SEHK:2496Biotechs
Wuhan YZY Biopharma (SEHK:2496) Loss Deepens In 1H 2025 Challenging Improving Loss Trend Narrative
Wuhan YZY Biopharma (SEHK:2496) has just posted its FY 2025 first half numbers, with revenue of C¥44.4 million and a basic EPS loss of C¥0.30 per share, alongside trailing 12 month revenue of C¥149.3 million and a basic EPS loss of C¥0.40. Over recent periods the company has seen revenue move from C¥2.8 million in 1H 2024 to C¥105.0 million in 2H 2024 and C¥44.4 million in 1H 2025. Over the same intervals, EPS shifted from a loss of C¥0.40 to a loss of C¥0.10 and then a loss of C¥0.30 per...